FGF19 and metabolic dysfunction-associated steatotic liver disease: Increasingly promising mouse and human experiment data support the idea that FGFs (FGF19 and FGF21) can prevent the onset and progression of NAFLD by inhibiting hepatic fat accumulation, excessive inflammation, hepatocyte damage, and fibrosis.